EOM Pharmaceuticals Inc. (IMMUNOCELLULAR THERAPEUTICS LTD.)

Company Snapshot

Founded: 2020
Entity Type: Private
Region: U.S.
Headquarter: New Jersey, U.S.
Key Geographics: North America
Corporate Address: 136 Summit Avenue Suite 100, Montvale New Jersey 07645 U.S. Tel. +1-(201)-351-0605 www.eompharma.com

Company Overview

ImmunoCellular Therapeutics Ltd. is a clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. Its proprietary technology includes cancer immunotherapy, dendritic cell (DC)-based immunotherapies and a stem-to-T-cell platform. The cancer immunotherapeutic activates the body’s immune system against multiple tumor-associated antigens, which are overexpressed on cancer stem cells and other cancer cells. DC-based immunotherapeutics are developed from the patients’ own cells, which offers antigens to the immune system. The stem-to-T-cell platform helps to kill the tumor by creating a population of antigen specific T cells.

EOM Pharmaceuticals Inc. (IMMUNOCELLULAR THERAPEUTICS LTD.) In Reports

Next-Generation Cancer Diagnostics: Technologies and Global Markets

BCC Research Market Report says next-generation cancer diagnostics market reached $8.7 billion in 2022 and should reach $15 billion by 2027, with a CAGR of 11.5%.

Global Microarray Market

BCC Research Market Report for Microarray. A comprehensive overview of the global markets for microarray technologies.

Cancer Stem Cells: Technologies and Global Markets

BCC Research Market Report for Cancer Stem Cells industry. Cancer Stem Cells therapeutics market size and analyses of global market trends, with CAGRs through 2026.

Company's Business Segments

  • Drugs Development : The company engaged in developing drugs that could transform therapeutic paradigms and improve the quality of life for patients suffering from debilitating and infectious diseases, autoimmune diseases (rheumatoid arthritis), and cachexia associated with AIDS and cancer.

Applications/End User Industries

  • Healthcare
  • Life Sciences
AI Sentiment